Pharmacology: SPORETIK contains Cefixime, a semisynthetic third generation cephalosporin antibiotic for oral administration.
The bactericidal action of SPORETIK results from inhibition of cell-wall synthesis.
SPORETIK is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to SPORETIK.
SPORETIK has been shown to be active against most of the following organisms both in vitro and in clinical infections: Gram-positive organisms: Streptococcus pneumoniae; Streptococcus pyogenes.
Gram-negative organisms: Haemophilus influenzae (beta-lactamase positive); Moraxella (Branhamella) catarrhalis (most of which are beta-lactamase positive); Escherichia coli; Proteus mirabilis.
SPORETIK has been shown to be active in vitro against most strains of the following organisms: Gram-positive organisms: Streptococcus agalactiae.
Gram-negative organisms: Neisseria gonorrhoeae (beta-lactamase positive and negative strains); Haemophilus parainfluenzae (beta-lactamase positive and negative strains); Proteus vulgaris; Pasteurella multocida; Providencia sp.; Serratia marcescens; Salmonella sp.; Shigella sp.; Citrobacter amalonaticus.
The average serum half-life of Cefixime in healthy subjects is 3 to 4 hours. In subjects with moderate impairment of renal function the average serum half-life of Cefixime is prolonged to 6.4 hours and in severe renal impairment the half-life increased to an average of 11.5 hours.